Lundbeck receives FDA Fast Track designation for Lu AH69593, an investigational orexin 2 receptor agonist for narcolepsy

RegulatoryLu AH69593Positive

AI Analysis

Summary

The FDA granted Fast Track designation to Lundbeck's Lu AH69593, an oral orexin 2 receptor agonist, for the treatment of narcolepsy. Fast Track status is intended to facilitate development and expedite review of drugs addressing serious conditions.

Outcome Details

Fast Track designation granted

Importance:6/10

Sentiment:

0.70

FDAFast Tracknarcolepsyorexin 2 receptor agonistLundbeck

Related Companies

$HLUYY

Read the original article

Published by PR Newswire Biotech on July 23, 2026 7:29 AM

Read Original